Peutz–Jeghers syndrome (PJS, MIM175200) is an autosomal dominant condition defined by
the development of characteristic polyps throughout the gastrointestinal tract and …

Critical driver genomic events in colorectal cancer have been shown to affect the response
to targeted agents that were initially developed under the'one gene, one drug'paradigm of …

The discovery of mutant KRAS as a predictor of resistance to epidermal growth-factor
receptor (EGFR) monoclonal antibodies brought a major change in the treatment of …

Background We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and
leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought …

Colorectal cancer (CRC) is a frequently lethal disease with heterogeneous outcomes and
drug responses. To resolve inconsistencies among the reported gene expression–based …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

Background Following the discovery that mutant KRAS is associated with resistance to anti-
epidermal growth factor receptor (EGFR) antibodies, the tumours of patients with metastatic …

Purpose The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as
first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of …

Purpose Mutations within the KRAS proto-oncogene have predictive value but are of
uncertain prognostic value in the treatment of advanced colorectal cancer. We took …

Background KRAS mutation status is a candidate marker for predicting survival in patients
with metastatic colorectal cancer (mCRC) treated with cetuximab (CTX). Patients and …